[Primary prevention with aspirin]. / Prevención primaria con aspirina.

The benefit of acetylsalicylic acid and other antiplatelet drugs in secondary prevention is well established, however it use in primary prevention continues to be controversial. On the one hand, the benefit obtained is very near the potential damage arising from its use (mainly gastrointestinal bleeding), and on the other, the net benefit is less, given that its aim is to prevent the occurrence of vascular events in situations with a lower baseline risk. Antiplatelet treatment with aspirin in primary prevention has been evaluated in clinical trials and several meta-analyses, comparing its efficacy with a placebo, and with results noted for their heterogeneity. The mechanisms of action of different antiplatelet drugs, as well as the existing evidence with aspirin in primary prevention, the directions for its use by different Scientific Societies, and the cost/benefit of the intervention are reviewed.

Prevención primaria con aspirina / Primary prevention with aspirin

El beneficio del ácido acetil-salicílico o de otros antiagregantes en la prevención secundaria está bien establecido; sin embargo, el uso de antiagregación en la prevención primaria sigue siendo un motivo de controversia, por una parte, el beneficio obtenido está muy cercano al daño potencial derivado de su uso (principalmente hemorragias digestivas); por lo que el beneficio neto es menor, dado que su objetivo es evitar la aparición de eventos vasculares en situaciones con un riesgo basal inferior. El tratamiento antiagregante con aspirina en prevención primaria ha sido evaluado en ensayos clínicos y diversos metaanálisis comparando su eficacia con placebo y los resultados se caracterizan por su heterogeneidad. Se revisan en este manuscrito los mecanismos de acción de diferentes antiagregantes, las evidencias que existen con aspirina en prevención primaria, las directrices para su uso de diferentes Sociedades Científicas y el coste beneficio de la intervención (AU)

The benefit of acetylsalicylic acid and other antiplatelet drugs in secondary prevention is well established, however it use in primary prevention continues to be controversial. On the one hand, the benefit obtained is very near the potential damage arising from its use (mainly gastrointestinal bleeding), and on the other, the net benefit is less, given that its aim is to prevent the occurrence of vascular events in situations with a lower baseline risk. Antiplatelet treatment with aspirin in primary prevention has been evaluated in clinical trials and several meta-analyses, comparing its efficacy with a placebo, and with results noted for their heterogeneity. The mechanisms of action of different antiplatelet drugs, as well as the existing evidence with aspirin in primary prevention, the directions for its use by different Scientific Societies, and the cost/benefit of the intervention are reviewed (AU)

Nuevo método de inserción de la mascarilla laríngea proseal mediante sonda de aspiración en un caso de vía aérea difícil / No disponible

No disponible